These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 36206367)

  • 1. Engineered DBCO+PD-1 Nanovesicles Carrying 1-MT for Cancer-Targeted Immunotherapy.
    Xu X; Liu L; Wang H; Li W; Zou Y; Zeng Y; Yang Q; Bai D; Dai D
    ACS Biomater Sci Eng; 2022 Nov; 8(11):4819-4826. PubMed ID: 36206367
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genetic engineering cellular vesicles expressing CD64 as checkpoint antibody carrier for cancer immunotherapy.
    Li L; Miao Q; Meng F; Li B; Xue T; Fang T; Zhang Z; Zhang J; Ye X; Kang Y; Zhang X; Chen Q; Liang X; Chen H; Zhang X
    Theranostics; 2021; 11(12):6033-6043. PubMed ID: 33897897
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genetically engineered PD-1 displaying nanovesicles for synergistic checkpoint blockades and chemo-metabolic therapy against non-small cell lung cancer.
    Li B; Yang T; Liu J; Yu X; Li X; Qin F; Zheng J; Liang J; Zeng Y; Zhou Z; Liu L; Zhang B; Yao W; Feng Z; Zeng G; Zhou Q; Chen L
    Acta Biomater; 2023 Apr; 161():184-200. PubMed ID: 36893957
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PD-1 Blockade Cellular Vesicles for Cancer Immunotherapy.
    Zhang X; Wang C; Wang J; Hu Q; Langworthy B; Ye Y; Sun W; Lin J; Wang T; Fine J; Cheng H; Dotti G; Huang P; Gu Z
    Adv Mater; 2018 May; 30(22):e1707112. PubMed ID: 29656492
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hybrid Cellular Nanovesicles Block PD-L1 Signal and Repolarize M2 Macrophages for Cancer Immunotherapy.
    Zhao C; Pan Y; Liu L; Zhang J; Wu X; Liu Y; Zhao XZ; Rao L
    Small; 2024 Aug; 20(31):e2311702. PubMed ID: 38456371
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genetically engineered cellular nanoparticles loaded with curcuminoids for cancer immunotherapy.
    Liao Y; Zhao C; Pan Y; Guo Y; Liu L; Wu J; Zhang Y; Rao L; Li Q
    Theranostics; 2024; 14(16):6409-6425. PubMed ID: 39431008
    [No Abstract]   [Full Text] [Related]  

  • 7. Disruption of SIRT7 Increases the Efficacy of Checkpoint Inhibitor via MEF2D Regulation of Programmed Cell Death 1 Ligand 1 in Hepatocellular Carcinoma Cells.
    Xiang J; Zhang N; Sun H; Su L; Zhang C; Xu H; Feng J; Wang M; Chen J; Liu L; Shan J; Shen J; Yang Z; Wang G; Zhou H; Prieto J; Ávila MA; Liu C; Qian C
    Gastroenterology; 2020 Feb; 158(3):664-678.e24. PubMed ID: 31678303
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PD-L1 cellular nanovesicles carrying rapamycin inhibit alloimmune responses in transplantation.
    Yang M; Xu Z; Yan H; Tsai HI; Su D; Yan F; Lu Q; Feng J; Zeng W; Xi L; Zha H; Ling Y; He C; Wu Y; Xu X; Zheng G; Liu G; Chen H; Cheng F
    Biomater Sci; 2021 Feb; 9(4):1246-1255. PubMed ID: 33367372
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Establishment of humanized tumor microenvironment mouse models based on the injection of peripheral blood mononuclear cells and IFN-γ to evaluate the efficacy of PD-L1/PD-1-targeted immunotherapy.
    Lin X; Zeng T; Lin J; Zhang Q; Cheng H; Fang S; Lin S; Chen Y; Xu Y; Lin J
    Cancer Biol Ther; 2020; 21(2):130-138. PubMed ID: 31690181
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Uncovering the colorectal cancer immunotherapeutic potential: Evening primrose (Oenothera biennis) root extract and its active compound oenothein B targeting the PD-1/PD-L1 blockade.
    Lee EJ; Kim YS; Kim JH; Woo KW; Park YH; Ha JH; Li W; Kim TI; An BK; Cho HW; Han JH; Choi JG; Chung HS
    Phytomedicine; 2024 Mar; 125():155370. PubMed ID: 38266440
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PD-1 Cellular Nanovesicles Carrying Gemcitabine to Inhibit the Proliferation of Triple Negative Breast Cancer Cell.
    Zha H; Xu Z; Xu X; Lu X; Shi P; Xiao Y; Tsai HI; Su D; Cheng F; Cheng X; Chen H
    Pharmaceutics; 2022 Jun; 14(6):. PubMed ID: 35745835
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Engineering Programmed Death Ligand-1/Cytotoxic T-Lymphocyte-Associated Antigen-4 Dual-Targeting Nanovesicles for Immunosuppressive Therapy in Transplantation.
    Xu Z; Tsai HI; Xiao Y; Wu Y; Su D; Yang M; Zha H; Yan F; Liu X; Cheng F; Chen H
    ACS Nano; 2020 Jul; 14(7):7959-7969. PubMed ID: 32515579
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of T-cell-mediated immune response via the PD-1/ PD-L1 axis in cholangiocarcinoma cells.
    Suriyo T; Fuangthong M; Artpradit C; Ungtrakul T; Sricharunrat T; Taha F; Satayavivad J
    Eur J Pharmacol; 2021 Apr; 897():173960. PubMed ID: 33617828
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Peptide vaccine-conjugated mesoporous carriers synergize with immunogenic cell death and PD-L1 blockade for amplified immunotherapy of metastatic spinal.
    Wang Z; Chen L; Ma Y; Li X; Hu A; Wang H; Wang W; Li X; Tian B; Dong J
    J Nanobiotechnology; 2021 Aug; 19(1):243. PubMed ID: 34384429
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Macitentan improves antitumor immune responses by inhibiting the secretion of tumor-derived extracellular vesicle PD-L1.
    Lee CH; Bae JH; Choe EJ; Park JM; Park SS; Cho HJ; Song BJ; Baek MC
    Theranostics; 2022; 12(5):1971-1987. PubMed ID: 35265193
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Roles of PD-1/PD-L1 Pathway: Signaling, Cancer, and Beyond.
    Ai L; Xu A; Xu J
    Adv Exp Med Biol; 2020; 1248():33-59. PubMed ID: 32185706
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Establishment of peripheral blood mononuclear cell-derived humanized lung cancer mouse models for studying efficacy of PD-L1/PD-1 targeted immunotherapy.
    Lin S; Huang G; Cheng L; Li Z; Xiao Y; Deng Q; Jiang Y; Li B; Lin S; Wang S; Wu Q; Yao H; Cao S; Li Y; Liu P; Wei W; Pei D; Yao Y; Wen Z; Zhang X; Wu Y; Zhang Z; Cui S; Sun X; Qian X; Li P
    MAbs; 2018; 10(8):1301-1311. PubMed ID: 30204048
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sensitizing tumors to anti-PD-1 therapy by promoting NK and CD8+ T cells via pharmacological activation of FOXO3.
    Chung YM; Khan PP; Wang H; Tsai WB; Qiao Y; Yu B; Larrick JW; Hu MC
    J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34887262
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Programmed Cell Death-1: Programmed Cell Death-Ligand 1 Interaction Protects Human Cardiomyocytes Against T-Cell Mediated Inflammation and Apoptosis Response In Vitro.
    Tay WT; Fang YH; Beh ST; Liu YW; Hsu LW; Yen CJ; Liu PY
    Int J Mol Sci; 2020 Mar; 21(7):. PubMed ID: 32244307
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A PD-L1 and VEGFR2 dual targeted peptide and its combination with irradiation for cancer immunotherapy.
    Jiao L; Dong Q; Zhai W; Zhao W; Shi P; Wu Y; Zhou X; Gao Y
    Pharmacol Res; 2022 Aug; 182():106343. PubMed ID: 35798286
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.